Last quarter (Q3 2025), Larimar Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Larimar Therapeutics's net income was $-47.71M. See Larimar Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ -155.00K
Operating Expenses	$ 90.89M	$ 41.76M	$ 36.53M	$ 50.47M	$ 42.65M
Depreciation and Amortization	$ 318.00K	$ 311.00K	$ 318.00K	$ 326.00K	$ 155.00K
EBITDA	$ -90.57M	$ -41.45M	$ -36.21M	$ -50.14M	$ -42.65M
Operating Income	$ -90.89M	$ -41.76M	$ -36.53M	$ -50.47M	$ -42.80M
Other Income/Expenses	$ 10.29M	$ 4.81M	$ 1.17M	$ -171.00K	$ 322.00K
Pretax Income	$ -80.60M	$ -36.95M	$ -35.35M	$ -50.64M	$ -42.48M
Net Income	$ -80.60M	$ -36.95M	$ -35.35M	$ -50.64M	$ -42.33M
Per Share Metrics
Basic EPS	$ -1.32	$ -0.84	$ -1.33	$ -2.93	$ -3.56
Diluted EPS	$ -1.32	$ -0.84	$ -1.33	$ -2.93	$ -3.56
Weighted Average Shares Outstanding	61.26M	43.90M	25.76M	17.16M	11.88M
Weighted Average Shares Outstanding (Diluted)	61.26M	43.90M	25.76M	17.16M	11.88M

Currency in USD

Larimar Therapeutics Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing